Journal of Rheumatic Diseases

Table. 2.

Concomitant treatment after rituximab therapy in normal and decreased glomerular filtration rate groups

Variable Normal GFR (n=11) Decreased GFR (n=11) p-value
0∼6 months
Cyclophosphamide 1 (9.1) 0 (0) 1.000
Mycophenolate mofetil 8 (72.7) 4 (36.4) 0.087
Azathioprine 1 (9.1) 1 (9.1) 1.000
Tacrolimus 8 (72.7) 4 (36.4) 0.087
Hydroxychloroquine 11 (100) 8 (72.7) 0.214
Glucocorticoid 9 (81.8) 8 (72.7) 1.000
Prednisolone dose (mg/day) 7.9 (0.4∼12.7) 6.2 (0∼12.4) 0.606
Re-infusion of rituximab 0 (0) 0 (0) N/A
6∼12 months
Cyclophosphamide 0 (0) 1 (9.1) 1.000
Mycophenolate mofetil 9 (81.8) 5 (45.5) 0.183
Azathioprine 1 (9.1) 1 (9.1) 1.000
Tacrolimus 9 (81.8) 3 (27.3) 0.030
Hydroxychloroquine 11 (100) 8 (72.7) 0.214
Glucocorticoid 8 (72.7) 8 (72.7) 1.000
Prednisolone dose (mg/day) 5.8 (0∼14.5) 2.9 (0∼11.4) 0.562
Re-infusion of rituximab 1 (9.1) 1 (9.1) 1.000

Data are expressed as median (interquartile range) or number (%). GFR: glomerular filtration rate, N/A: not available.

J Rheum Dis 2022;29:22~32 https://doi.org/10.4078/jrd.2022.29.1.22
© J Rheum Dis